Increased Research and Development Activities Driving Expansion of Global Hemophilia Treatment Drugs Market: TMR

This article was originally published on this site

– Hemophilia treatment drugs market is likely to show growth at a decent CAGR of around 5% during forecast period 2018–2026. Growing focus of industry leaders on development of novel drugs for hemophilia treatment will fuel market expansion  

The North America hemophilia treatment drugs market is foreseen to dominate during assessment period

ALBANY, N.Y., Nov. 18, 2020 /PRNewswire/ — Hemophilia is a rare health condition in which an individual’s blood is not able to clot normally due to lack of adequate blood-clotting factors. Enterprises working in the global hemophilia treatment drugs market are consistently focused on the development of novel and more efficient drugs. To achieve this motive, many players in this market are pouring investments in research and development activities.

Analysts at TMR highlight that the global hemophilia treatment drugs market is estimated to show upward curve of revenues during the assessment period of 2018 to 2026. One of the important factors driving market growth is remarkable increase in number of hemophilia patients. This aside, towering demand for effective hemophilia treatment options from all across the globe is likely to boost the market expansion. Thus, the global hemophilia treatment drugs market is predicted to gain the valuation of around US$ 15,000 Mn by the end of assessment period.

Request for Analysis of COVID-19 Impact on Hemophilia Treatment Drugs Market –

Key Findings of Hemophilia Treatment Drugs Market Report

  • The global hemophilia treatment drugs market is foreseen to demonstrate growth at 5% a CAGR during 2018–2026.
  • Thus, the market is likely to gather valuation of almost US$ 15,000 Mn by the end of 2026.
  • The total valuation of the market for hemophilia treatment drugs was approximately US$ 9,500 Mn in 2017.
  • Of all product types, the recombinant coagulation factor concentrates segment is foreseen to hold major market share during 2018–2026.
  • In terms of products, the hemophilia A segment held lion’s share of the hemophilia treatment drugs market in 2017.
  • Of all distribution channels, the hospital pharmacies segment was accounted for major market share in 2017.
  • The above-mentioned segment is estimated to maintain its leading position in the forthcoming years.
  • North America was dominant region in hemophilia treatment drugs market during 2017.
  • The aforementioned region is foreseen to maintain its dominant position during forthcoming years.

Explore 188 pages of top-notch research, incisive insights, and detailed country-level projections on Hemophilia Treatment Drugs Market (Product Type – Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates; Disease Indication – Hemophilia A, Hemophilia B, Others; Distribution Channel – Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2026 at

Hemophilia Treatment Drugs Market: Key Driving Factors and Promising Avenues

  • The global hemophilia treatment drugs market is predicted to show upward curve of revenue during assessment period of 2018 to 2026. This growth is attributed to ascending graph of demand for long-acting replacement therapies as well as non-factor therapies from the worldwide healthcare sector.
  • The government bodies of many countries across the globe are taking initiatives to offer advanced treatment options for hemophilia patients. For instance, the Federal Government in the U.S. provides financial support for the nationwide network of hemophilia treatment centers (HTCs). This factor is pushing the growth of the hemophilia treatment drugs market in the region.
  • In addition to this, the regulatory authorities of many countries together with non-profitable organizations across the globe are organizing various campaigns to increase awareness about the early hemophilia screening of neonates. This factor is likely to push the hemophilia treatment drugs market growth in the forthcoming years.

Purchase the Hemophilia Treatment Drugs Market Report –

Hemophilia Treatment Drugs Market: Competitive Assessment

  • Major players operating in the hemophilia treatment drugs market are using diverse strategies to maintain their leading position in the market. Thus, they are growing focus on using various strategies including mergers, acquisitions, partnerships, and collaborations.
  • The list of important companies working in the hemophilia treatment drugs market includes Pfizer, Inc., Shire plc, Kedrion, Bayer AG, Novo Nordisk A/S, Sanofi, CSL Behring, and F. Hoffmann-La Roche Ltd.

Browse More Press Release –

The hemophilia treatment drugs market can be segmented as follows:


  • Recombinant coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Others
  • Plasma-derived coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Others
  • Others

Disease Indication

  • Hemophilia A
  • Hemophilia B
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC countries
    • Rest of MEA

Explore Transparency Market Research’s award-winning coverage of the global Healthcare Industry:

Plasma Protein Therapeutics Market: According to the report, the Plasma Protein Therapeutics Market was valued at US$ 22.41 Bn in 2018 and is projected to expand at a CAGR of 7.0% from 2019 to 2027, growing Investment in Innovation, Rising Demand for Immunoglobulin (IG), Rising Indications and Therapeutic use of Plasma Derived Protein Therapeutics are projected to drive the market

Rare Hematology Market: According to Transparency Market Research, the worldwide rare hematology market is anticipated to rise at 6.2% of CAGR, with a value of over US$16000 mn by the end of the forecast period which is from 2017-2022. Presently, the global hematology market on the basis of age is anticipated to show the highest rise in terms of revenue, valuing over US$3000 mn.

Hemostasis Products Market: Transparency Market Research states that the global hemostasis products market will expand at a healthy 4.2% CAGR over the period between 2016 and 2024. Growing at this pace, the market, which had a valuation of US$5.35 bn in 2015, is expected to rise to US$7.73 bn in 2024. The rising numbers of trauma cases and complex surgeries, rising geriatric population and high investment is research and development are driving the market

Browse Our Latest Reports –

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”

Browse More Upcoming Reports by Transparency Market Research:

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
USA – Canada Toll Free: 866-552-3453
Press Release Source: